Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV), formally designated the human herpesvirus 8 (HHV-8), is the causative agent of Kaposi’s sarcoma, primary effusion lymphoma, and is also associated with the plasmablastic variant of multicentric Castleman’s disease (MCD). More recently, KSHV has been linked to another pathological condition with many features in common with MCD, named KSHV inflammatory cytokine syndrome (KICS). KSHV infection is highly prevalent in sub-Saharan Africa and among some Amerindian and Melanesian populations, and diffuse in the Mediterranean area, in some Middle Eastern countries, and in parts of South America. KSHV is less prevalent in Northern Europe, North America and most of Asia. KSHV is transmitted via nonsexual routes during childhood in regions with intermediate and high seroprevalence, and mainly via sexual contact during adulthood in countries with low seroprevalence. Saliva is an important reservoir of infectious virus and plays a central role in both sexual and nonsexual modalities of transmission. KSHV is equipped with unique and host-pirated gene products with oncogenic properties and ability to increase the survival and proliferation of infected cells, modulate cellular microRNAs, and induce genetic instability. KSHV encodes a set of microRNAs that provide alternative strategy to modulate host gene expression while avoiding recognition by the host immune system. In vitro studies, animal models and recombinant viruses have greatly increased our knowledge of the KSHV-driven pathogenic mechanisms. A distinctive characteristic of KSHV pathogenesis is that genes expressed during the lytic phase generate an inflammatory microenvironment that cooperates with latent genes and viral microRNAs in cell immortalization and transformation. Several aspects of KSHV-induced pathogenesis and many of the predisposing factors remain to be revealed, and only a small part of the new findings has been translated into an effective clinical practice. Globally useful or population-based prognostic and predictive biomarkers for KSHV-related disorders still need to be defined to guide physicians in the choice of therapeutic strategies and to selectively monitor patients at risk. In the future, new technological tools, such as digital PCR and next-generation sequencing, are expected to provide new diagnostic assays and to extend and refine our knowledge on KSHV.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ablashi D, Chatlynne L, Cooper H, Thomas D, Yadav M, et al. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer. 1999;81:893–7.
Ahmad A, Groshong JS, Matta H, Schamus S, Punj V, et al. Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. Cancer Biol Ther. 2010;10:1033–40.
Akula SM, Wang FZ, Vieira J, Chandran B. Human herpesvirus 8 interaction with target cells involves heparan sulfate. Virology. 2001;282:245–55.
Alzahrani AJ, El Harith e-HA, Milzer J, Obeid OE, Stuhrmann M, et al. Increased seroprevalence of human herpes virus-8 in renal transplant recipients in Saudi Arabia. Nephrol Dial Transplant. 2005;20:2532–6.
Amir H, Kaaya E, Kwesigabo G, Kitinya J, Biberfeld P. Kaposi’s sarcoma before and during the HIV epidemic in Tanzania. Int J Oncol. 1997;11:1363–6.
Amir H, Kaaya EE, Manji KP, Kwesigabo G, Biberfeld P. Kaposi’s sarcoma before and during a human immunodeficiency virus epidemic in Tanzanian children. Pediatr Infect Dis J. 2001;20:518–21.
An FQ, Compitello N, Horwitz E, Sramkoski M, Knudsen ES, Renne R. The latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J Biol Chem. 2005;280:3862–74.
Andreoni M, El-Sawaf G, Rezza G, Ensoli B, Nicastri E, et al. High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. J Natl Cancer Inst. 1999;91:465–9.
Andreoni M, Goletti D, Pezzotti P, Pozzetto A, Monini P, et al. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi’s sarcoma in renal and liver transplant recipients. J Infect. 2001;43:195–9.
Angeloni A, Heston L, Uccini S, Sirianni MC, Cottoni F, et al. High prevalence of antibodies to human herpesvirus 8 in relatives of patients with classic Kaposi’s sarcoma from Sardinia. J Infect Dis. 1998;177:1715–8.
Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood. 1999;94:4247–54.
Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, et al. Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93:4034–43.
Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, Holdorf M, Weissman JS, Ganem D. KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog. 2014;10:e1003847.
Ariyoshi K, Schim van der Loeff M, Cook P, Whitby D, Corrah T, et al. Kaposi’s sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol. 1998;1:193–9.
Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein- coupled receptor linked to cell proliferation. Nature. 1997;385:347–50.
Ascoli V, Calabro ML, Giannakakis K, Barbierato M, Chieco-Bianchi L, et al. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8-associated polyclonal body cavity effusions that mimic primary effusion lymphomas. Int J Cancer. 2006;119:1746–8; author reply 9–50.
Atkinson J, Edlin BR, Engels EA, Kral AH, Seal K, et al. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis. 2003;187:974–81.
Austgen K, Oakes SA, Ganem D. Multiple defects, including premature apoptosis, prevent Kaposi’s sarcoma-associated herpesvirus replication in murine cells. J Virol. 2012;86:1877–82.
Baeten JM, Chohan BH, Lavreys L, Rakwar JP, Ashley R, et al. Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya. AIDS. 2002;16:2073–8.
Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, et al. G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86–9.
Balachandra B, Tunitsky E, Dawood S, Hings I, Marcus VA. Classic Kaposi’s sarcoma presenting first with gastrointestinal tract involvement in a HIV-negative Inuit male–a case report and review of the literature. Pathol Res Pract. 2006;202:623–6.
Ballestas ME, Kaye KM. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J Virol. 2001;75:3250–8.
Ballestas ME, Kaye KM. The latency-associated nuclear antigen, a multifunctional protein central to Kaposi’s sarcoma-associated herpesvirus latency. Future Microbiol. 2011;6:1399–413.
Barozzi P, Luppi M, Facchetti F, Mecucci C, Alu M, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med. 2003;9:554–61.
Barozzi P, Bonini C, Potenza L, Masetti M, Cappelli G, et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation. 2008;86:738–44.
Bechtel JT, Liang Y, Hvidding J, Ganem D. Host range of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol. 2003;77:6474–81.
Bechtel JT, Winant RC, Ganem D. Host and viral proteins in the virion of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2005;79:4952–64.
Benelli R, Albini A, Parravicini C, Carlone S, Repetto L, et al. Isolation of spindle-shaped cell populations from primary cultures of Kaposi’s sarcoma of different stage. Cancer Lett. 1996;100:125–32.
Beral V. Epidemiology of Kaposi’s sarcoma. Cancer Surv. 1991;10:5–22.
Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335:123–8.
Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103:4368–9.
Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010;115:4455–63.
Biggar RJ, Horm J, Fraumeni Jr JF, Greene MH, Goedert JJ. Incidence of Kaposi’s sarcoma and mycosis fungoides in the United States including Puerto Rico, 1973–81. J Natl Cancer Inst. 1984;73:89–94.
Biggar RJ, Whitby D, Marshall V, Linhares AC, Black F. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis. 2000;181:1562–8.
Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962–72.
Bigoni B, Dolcetti R, de Lellis L, Carbone A, Boiocchi M, et al. Human herpesvirus 8 is present in the lymphoid system of healthy persons and can reactivate in the course of AIDS. J Infect Dis. 1996;173:542–9.
Bihl F, Mosam A, Henry LN, Chisholm 3rd JV, Dollard S, et al. Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. AIDS. 2007;21:1245–52.
Biryahwaho B, Dollard SC, Pfeiffer RM, Shebl FM, Munuo S, et al. Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda. J Infect Dis. 2010;202:1347–53.
Blackbourn DJ, Osmond D, Levy JA, Lennette ET. Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. J Infect Dis. 1999;179:237–9.
Blackbourn DJ, Fujimura S, Kutzkey T, Levy JA. Induction of human herpesvirus-8 gene expression by recombinant interferon gamma. AIDS. 2000;14:98–9.
Boshoff C, Talbot S, Kennedy M, O’Leary J, Schulz T, Chang Y. HHV8 and skin cancers in immunosuppressed patients. Lancet. 1996;348:138.
Boshoff C, Gao SJ, Healy LE, Matthews S, Thomas AJ, et al. Establishing a KSHV + cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood. 1998;91:1671–9.
Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23:4372–80.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10:321–2.
Braun M. Classics in oncology. Idiopathic multiple pigmented sarcoma of the skin by Kaposi. CA Cancer J Clin. 1982;32:340–7.
Brayfield BP, Phiri S, Kankasa C, Muyanga J, Mantina H, et al. Postnatal human herpesvirus 8 and human immunodeficiency virus type 1 infection in mothers and infants from Zambia. J Infect Dis. 2003;187:559–68.
Brown EE, Fallin D, Ruczinski I, Hutchinson A, Staats B, et al. Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol Biomarkers Prev. 2006;15:926–34.
Brown EE, Whitby D, Vitale F, Marshall V, Mbisa G, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer. 2006;107:2282–90.
Brulois KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, Lee SH, Lee HR, Myoung J, Ganem D, Oh TK, Kim JF, Gao SJ, Jung JU. Construction and manipulation of a new Kaposi’s sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol. 2012;86:9708–20.
Burbelo PD, Leahy HP, Groot S, Bishop LR, Miley W, et al. Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection. Clin Vaccine Immunol. 2009;16:621–7.
Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis. 2009;200:430–8.
Butler LM, Were WA, Balinandi S, Downing R, Dollard S, et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis. 2011;203:625–34.
Cai X, Cullen BR. Transcriptional origin of Kaposi’s sarcoma-associated herpesvirus microRNAs. J Virol. 2006;80:2234–42.
Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog. 2006;2:e116.
Calabro ML, Sheldon J, Favero A, Simpson GR, Fiore JR, et al. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. J Hum Virol. 1998;1:207–13.
Calabro ML, Fiore JR, Favero A, Lepera A, Saracino A, et al. Detection of human herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1-seropositive and -seronegative women. J Infect Dis. 1999;179:1534–7.
Calabro ML, Gasperini P, Barbierato M, Ometto L, Zanchetta M, et al. A search for human herpesvirus 8 (HHV-8) in HIV-1 infected mothers and their infants does not suggest vertical transmission of HHV-8. Int J Cancer. 2000;85:296–7.
Calabro ML, Gasperini P, Fiore JR, Barbierato M, Angarano G, Chieco-Bianchi L. Intrafamilial transmission of human herpesvirus 8. J Natl Cancer Inst. 2001;93:154–6.
Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi’s sarcoma clinical stage. AIDS. 2000;14:2109–16.
Cancer ICoHa. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823–30.
Cannon MJ, Dollard SC, Smith DK, Klein RS, Schuman P, et al. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med. 2001;344:637–43.
Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113:1213–24.
Carroll PA, Brazeau E, Lagunoff M. Kaposi’s sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology. 2004;328:7–18.
Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103:1632–4.
Cassar O, Blondot ML, Mohanna S, Jouvion G, Bravo F, et al. Human herpesvirus 8 genotype E in patients with Kaposi sarcoma, Peru. Emerg Infect Dis. 2010;16:1459–62.
Cassar O, Charavay F, Bassot S, Plancoulaine S, Grangeon JP, et al. Divergent KSHV/HHV-8 subtype D strains in New Caledonia and Solomon Islands, Melanesia. J Clin Virol. 2012;53:214–8.
Caterino-de-Araujo A. Human herpesvirus 8 group B and C variants circulating in Sao Paulo, Brazil. J Infect Dis. 1998;177:1136–7.
Caterino-de-Araujo A, Magri MC, Manuel RC. Patterns of antibodies against latent and lytic antigens of human herpesvirus 8 in an endemic population and patients with Kaposi’s sarcoma in Mozambique. J Med Virol. 2010;82:1576–81.
Cattani P, Cerimele F, Porta D, Graffeo R, Ranno S, et al. Age-specific seroprevalence of Human Herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect. 2003;9:274–9.
Cattelan A, Calabro M, Gasperini P, Aversa S, Zanchetta M, et al. Acquired immunodeficiency syndrome-related kaposi’s sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr. 2000;2000:44–9.
Cattelan AM, Calabro ML, De Rossi A, Aversa SM, Barbierato M, et al. Long-term clinical outcome of AIDS-related Kaposi’s sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005;27:779–85.
Cesarman E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 2011;305:163–74.
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–91.
Chakraborty S, Veettil MV, Chandran B. Kaposi’s Sarcoma associated herpesvirus entry into target cells. Front Microbiol. 2012;3:6.
Challine D, Roudot-Thoraval F, Sarah T, Laperche L, Boisson B, et al. Seroprevalence of human herpes virus 8 antibody in populations at high or low risk of transfusion, graft, or sexual transmission of viruses. Transfusion. 2001;41:1120–5.
Chandriani S, Xu Y, Ganem D. The lytic transcriptome of Kaposi’s sarcoma-associated herpesvirus reveals extensive transcription of noncoding regions, including regions antisense to important genes. J Virol. 2010;84:7934–42.
Chang HH, Ganem D. A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe. 2013;13:429–40.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9.
Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska T, et al. Cyclin encoded by KS herpesvirus. Nature. 1996;382:410.
Chang J, Renne R, Dittmer D, Ganem D. Inflammatory cytokines and the reactivation of Kaposi’s sarcoma-associated herpesvirus lytic replication. Virology. 2000;266:17–25.
Chang PJ, Shedd D, Gradoville L, Cho MS, Chen LW, et al. Open reading frame 50 protein of Kaposi’s sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J Virol. 2002;76:3168–78.
Chang H, Wachtman LM, Pearson CB, Lee JS, Lee HR, et al. Non-human primate model of Kaposi’s sarcoma-associated herpesvirus infection. PLoS Pathog. 2009;5:e1000606.
Chang TY, Wu YH, Cheng CC, Wang HW. Differentially regulated splice variants and systems biology analysis of Kaposi’s sarcoma-associated herpesvirus-infected lymphatic endothelial cells. Nucleic Acids Res. 2011;39:6970–85.
Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore PS. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science. 2002;298:1432–5.
Chen J, Ueda K, Sakakibara S, Okuno T, Parravicini C, et al. Activation of latent Kaposi’s sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci U S A. 2001;98:4119–24.
Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP. Distinct p53, p53:LANA, and LANA complexes in Kaposi’s Sarcoma–associated Herpesvirus Lymphomas. J Virol. 2010;84:3898–908.
Chironna M, Tosatti MA, Di Gangi IM, Sallustio A, Germinario C, et al. High human herpesvirus 8 seroprevalence in populations from Western Balkan countries. J Med Virol. 2006;78:933–7.
Chugh PE, Sin SH, Ozgur S, Henry DH, Menezes P, Griffith J, Eron JJ, Damania B, Dittmer DP. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog. 2013;9:e1003484.
Ciufo DM, Cannon JS, Poole LJ, Wu FY, Murray P, et al. Spindle cell conversion by Kaposi’s sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J Virol. 2001;75:5614–26.
Cohen A, Wolf DG, Guttman-Yassky E, Sarid R. Kaposi’s sarcoma-associated herpesvirus: clinical, diagnostic, and epidemiological aspects. Crit Rev Clin Lab Sci. 2005;42:101–53.
Coluzzi M, Calabro ML, Manno D, Chieco-Bianchi L, Schulz TF, Ascoli V. Saliva and the transmission of human herpesvirus 8: potential role of promoter-arthropod bites. J Infect Dis. 2004;190:199–200.
Concato C, Diociaiuti A, Parisi F, Giraldi L, Ciasulli A, et al. Human herpesvirus-8 serology in pediatric organ transplantation. Transplant Proc. 2008;40:3683–4.
Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. The geographical distribution of Kaposi’s sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998;78:1521–8.
Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98:3473–5.
Coscoy L. Immune evasion by Kaposi’s sarcoma-associated herpesvirus. Nat Rev Immunol. 2007;7:391–401.
Cotter MA, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi’s sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology. 1999;264:254–64.
Cuomo ME, Knebel A, Morrice N, Paterson H, Cohen P, Mittnacht S. p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation. Nat Cell Biol. 2008;10:723–30.
Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005;352:1371–3.
Davidovici B, Karakis I, Bourboulia D, Ariad S, Zong JC, et al. Seroepidemiology and molecular epidemiology of Kaposi’s sarcoma-associated herpesvirus among Jewish population groups in Israel. J Natl Cancer Inst. 2001;93:194–202.
Davis MA, Sturzl MA, Blasig C, Schreier A, Guo HG, et al. Expression of human herpesvirus 8-encoded cyclin D in Kaposi’s sarcoma spindle cells. J Natl Cancer Inst. 1997;89:1868–74.
Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL, et al. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood. 2001;97:3244–50.
de Oliveira DE, Ballon G, Cesarman E. NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol. 2010;18:248–57.
de Sanjose S, Marshall V, Sola J, Palacio V, Almirall R, et al. Prevalence of Kaposi’s sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. Int J Cancer. 2002;98:155–8.
de Sanjose S, Mbisa G, Perez-Alvarez S, Benavente Y, Sukvirach S, et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis. 2009;199:1449–56.
de Souza VA, Pierrotti LC, Sumita LM, Freire WS, Segurado AA, Pannuti CS. Seroreactivity to Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi’s sarcoma patients depends on CD4+ T-cell count. J Med Virol. 2007;79:1562–8.
Dedicoat M, Newton R. Review of the distribution of Kaposi’s sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi’s sarcoma. Br J Cancer. 2003;88:1–3.
Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, et al. Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis. 2004;190:1068–75.
Deng B, O’Connor CM, Kedes DH, Zhou ZH. Cryo-electron tomography of Kaposi’s sarcoma-associated herpesvirus capsids reveals dynamic scaffolding structures essential to capsid assembly and maturation. J Struct Biol. 2008;161:419–27.
DeSantis SM, Pau CP, Archibald LK, Nwanyanwu OC, Kazembe PN, et al. Demographic and immune correlates of human herpesvirus 8 seropositivity in Malawi, Africa. Int J Infect Dis. 2002;6:266–71.
Desrosiers RC, Sasseville VG, Czajak SC, Zhang X, Mansfield KG, et al. A herpesvirus of rhesus monkeys related to the human Kaposi’s sarcoma- associated herpesvirus. J Virol. 1997;71:9764–9.
Di Bartolo DL, Cannon M, Liu YF, Renne R, Chadburn A, et al. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood. 2008;111:4731–40.
Di Stefano M, Calabro ML, Di Gangi IM, Cantatore S, Barbierato M, et al. In vitro and in vivo human herpesvirus 8 infection of placenta. PLoS One. 2008;3:e4073.
Dilnur P, Katano H, Wang ZH, Osakabe Y, Kudo M, et al. Classic type of Kaposi’s sarcoma and human herpesvirus 8 infection in Xinjiang, China. Pathol Int. 2001;51:845–52.
Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, Ganem D. A cluster of latently expressed genes in Kaposi’s sarcoma-associated herpesvirus. J Virol. 1998;72:8309–15.
Dittmer DP, Gonzalez CM, Vahrson W, DeWire SM, Hines-Boykin R, Damania B. Whole-genome transcription profiling of rhesus monkey rhadinovirus. J Virol. 2005;79:8637–50.
Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 1999;190:1025–32.
Dollard SC, Nelson KE, Ness PM, Stambolis V, Kuehnert MJ, et al. Possible transmission of human herpesvirus-8 by blood transfusion in a historical United States cohort. Transfusion. 2005;45:500–3.
Dollard SC, Butler LM, Jones AM, Mermin JH, Chidzonga M, et al. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the “Kaposi’s sarcoma belt”. Int J Cancer. 2010;127:2395–401.
Du MQ, Liu H, Diss TC, Ye H, Hamoudi RA, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97:2130–6.
Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007;60:1350–7.
Dupin N, Marcelin AG, Gorin I, Bossi P, Franck N, et al. Prevalence of human herpesvirus 8 infection measured by antibodies to a latent nuclear antigen in patients with various dermatologic diseases. Arch Dermatol. 1998;134:700–2.
Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96:4546–51.
Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–12.
Eltom MA, Mbulaiteye SM, Dada AJ, Whitby D, Biggar RJ. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. AIDS. 2002;16:2473–8.
Enbom M, Tolfvenstam T, Ghebrekidan H, Ruden U, Grandien M, et al. Seroprevalence of human herpes virus 8 in different Eritrean population groups. J Clin Virol. 1999;14:167–72.
Enbom M, Urassa W, Massambu C, Thorstensson R, Mhalu F, Linde A. Detection of human herpesvirus 8 DNA in serum from blood donors with HHV-8 antibodies indicates possible bloodborne virus transmission. J Med Virol. 2002;68:264–7.
Engels EA, Eastman H, Ablashi DV, Wilks RJ, Braham J, Manns A. Risk of transfusion-associated transmission of human herpesvirus 8. J Natl Cancer Inst. 1999;91:1773–5.
Engels EA, Sinclair MD, Biggar RJ, Whitby D, Ebbesen P, et al. Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. Int J Cancer. 2000;88:1003–8.
Engels EA, Biggar RJ, Marshall VA, Walters MA, Gamache CJ, et al. Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma. AIDS. 2003;17:1847–51.
Engels EA, Atkinson JO, Graubard BI, McQuillan GM, Gamache C, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. 2007;196:199–207.
Esteban M, Garcia MA, Domingo-Gil E, Arroyo J, Nombela C, Rivas C. The latency protein LANA2 from Kaposi’s sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. J Gen Virol. 2003;84:1463–70.
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–91.
Fakhari FD, Jeong JH, Kanan Y, Dittmer DP. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest. 2006;116:735–42.
Farge D. Kaposi’s sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med. 1993;2:339–43.
Fernandez L, Serraino D, Rezza G, Lence J, Ortiz RM, et al. Infection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, Cuba. Br J Cancer. 2002;87:1253–6.
Ferreira S, Sanabani S, Reis AD, Chamone DF, Sabino EC. Human herpesvirus type 8 among Brazilian blood donors. Transfusion. 2003;43:1764–5.
Field N, Low W, Daniels M, Howell S, Daviet L, et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci. 2003;116:3721–8.
Fiore JR, Volpe A, Tosatti MA, De Valentin L, Favia A, et al. High seroprevalence of human herpesvirus 8 (HHV-8) in HIV-1-infected pregnant women of Southeastern Italy: association with injection drug use and hepatitis C virus infection. J Med Virol. 2004;72:656–60.
Flore O, Rafii S, Ely S, O’Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi’s sarcoma- associated herpesvirus. Nature. 1998;394:588–92.
Foreman KE, Friborg J, Chandran B, Katano H, Sata T, et al. Injection of human herpesvirus-8 in human skin engrafted on SCID mice induces Kaposi’s sarcoma-like lesions. J Dermatol Sci. 2001;26:182–93.
Frances C, Mouquet C, Marcelin AG, Barete S, Agher R, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation. 2000;69:1776–9.
Frances C, Marcelin AG, Legendre C, Chevret S, Dussaix E, et al. The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am J Transplant. 2009;9:2580–6.
Franceschi S, Geddes M. Epidemiology of classic Kaposi’s sarcoma, with special reference to Mediterranean population. Tumori. 1995;81:308–14.
Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99:800–4.
Friborg Jr J, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999;402:889–94.
Fujii T, Taguchi H, Katano H, Mori S, Nakamura T, et al. Seroprevalence of human herpesvirus 8 in human immunodeficiency virus 1-positive and human immunodeficiency virus 1-negative populations in Japan. J Med Virol. 1999;57:159–62.
Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi’s sarcoma-associated herpesvirus latency. Nat Med. 2003;9:300–6.
Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM. Profile of patients with Kaposi’s sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol. 2005;23:1253–60.
Gambus G, Bourboulia D, Esteve A, Lahoz R, Rodriguez C, et al. Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. AIDS. 2001;15:1167–74.
Gandy SZ, Linnstaedt SD, Muralidhar S, Cashman KA, Rosenthal LJ, Casey JL. RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. J Virol. 2007;81:13544–51.
Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest. 2010;120:939–49.
Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med. 1996;335:233–41.
Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med. 1996;2:925–8.
Gasperini P, Barbierato M, Martinelli C, Rigotti P, Marchini F, et al. Use of a BJAB-derived cell line for isolation of human herpesvirus 8. J Clin Microbiol. 2005;43:2866–75.
Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, et al. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. Cancer Res. 2012;72:1157–69.
Gaye-Diallo A, Toure AT, Gessain A, Gueye-Ndiaye A, Ndour AN, et al. Preliminary study of human Herpesvirus type 8 infection in pregnant women in Dakar (Senegal). Bull Soc Pathol Exot. 2001;94:231–4.
Geddes M, Franceschi S, Barchielli A, Falcini F, Carli S, et al. Kaposi’s sarcoma in Italy before and after the AIDS epidemic. Br J Cancer. 1994;69:333–6.
Gerard L, Berezne A, Galicier L, Meignin V, Obadia M, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25:3350–6.
Gessain A, Mauclere P, van Beveren M, Plancoulaine S, Ayouba A, et al. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer. 1999;81:189–92.
Giraldo G, Beth E, Haguenau F. Herpes-type virus particles in tissue culture of Kaposi’s sarcoma from different geographic regions. J Natl Cancer Inst. 1972;49:1509–26.
Giraldo G, Beth E, Huang ES. Kaposi’s sarcoma and its relationship to cytomegalovirus (CMNV). III. CMV DNA and CMV early antigens in Kaposi’s sarcoma. Int J Cancer. 1980;26:23–9.
Gnann Jr JW, Pellett PE, Jaffe HW. Human herpesvirus 8 and Kaposi’s sarcoma in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30 Suppl 1:S72–6.
Godden-Kent D, Talbot SJ, Boshoff C, Chang Y, Moore P, et al. The cyclin encoded by Kaposi’s sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol. 1997;71:4193–8.
Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood. 2005;105:2510–8.
Goedert JJ, Kedes DH, Ganem D. Antibodies to human herpesvirus 8 in women and infants born in Haiti and the USA [letter]. Lancet. 1997;349:1368.
Goedert JJ, Vitale F, Lauria C, Serraino D, Tamburini M, et al. Risk factors for classical Kaposi’s sarcoma. J Natl Cancer Inst. 2002;94:1712–8.
Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature. 2007;450:1096–9.
Graffeo R, Ranno S, Marchetti S, Capodicasa N, Schito AM, et al. HHV 8 seroprevalence and transmission within Albanian family groups. New Microbiol. 2003;26:1–6.
Grisotto MG, Garin A, Martin AP, Jensen KK, Chan P, et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J Clin Invest. 2006;116:1264–73.
Grossman Z, Iscovich J, Schwartz F, Azizi E, Klepfish A, et al. Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8. Mayo Clin Proc. 2002;77:905–9.
Grossmann C, Podgrabinska S, Skobe M, Ganem D. Activation of NF-kappaB by the latent vFLIP gene of Kaposi’s sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J Virol. 2006;80:7179–85.
Grulich AE, Beral V, Swerdlow AJ. Kaposi’s sarcoma in England and Wales before the AIDS epidemic. Br J Cancer. 1992;66:1135–7.
Grulich AE, Cunningham P, Munier ML, Prestage G, Amin J, et al. Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia. Sex Health. 2005;2:13–8.
Grundhoff A, Ganem D. Mechanisms governing expression of the v-FLIP gene of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2001;75:1857–63.
Guadalupe M, Pollock BH, Westbrook S, Redding S, Bullock D, et al. Risk factors influencing antibody responses to Kaposi’s sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;56:83–90.
Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 2004;199:993–1003.
Guasparri I, Wu H, Cesarman E. The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep. 2006;7:114–9.
Guihot A, Dupin N, Marcelin AG, Gorin I, Bedin AS, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis. 2006;194:1078–88.
Guito J, Lukac DM. KSHV Rta promoter specification and viral reactivation. Front Microbiol. 2012;3:30.
Gurtsevich VE, Kadyrova EL, Chernova VA, Demidov LV, Gruzdev BM, et al. Search for HHV-8 associated diseases reservoir and spread paths of HHV-8 in Russia. Vopr Virusol. 2004;49:20–4.
Guttman-Yassky E, Bar-Chana M, Yukelson A, Linn S, Friedman-Birnbaum R, et al. Epidemiology of classic Kaposi’s sarcoma in the Israeli Jewish population between 1960 and 1998. Br J Cancer. 2003;89:1657–60.
Guttman-Yassky E, Cohen A, Kra-Oz Z, Friedman-Birnbaum R, Sprecher E, et al. Familial clustering of classic Kaposi sarcoma. J Infect Dis. 2004;189:2023–6.
Guttman-Yassky E, Kra-Oz Z, Dubnov J, Friedman-Birnbaum R, Segal I, et al. Infection with Kaposi’s sarcoma-associated herpesvirus among families of patients with classic Kaposi’s sarcoma. Arch Dermatol. 2005;141:1429–34.
Guttman-Yassky E, Abada R, Kra-Oz Z, Sattinger J, Perelman A, et al. Relationship between human herpesvirus 8 loads and disease stage in classic Kaposi sarcoma patients. Diagn Microbiol Infect Dis. 2007;57:387–92.
Hahn AS, Kaufmann JK, Wies E, Naschberger E, Panteleev-Ivlev J, et al. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi’s sarcoma-associated herpesvirus. Nat Med. 2012;18(6):961–6.
Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006;17:1849–50.
Hannachi N, Ben Fredj N, Samoud S, Ferjani A, Khlif A, et al. [Seroprevalence and risk factors of human herpes virus 8 infection in Central-East Tunisia]. Pathol Biol. 2012;60:282–6.
Hansen A, Henderson S, Lagos D, Nikitenko L, Coulter E, et al. KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev. 2010;24:195–205.
Harwood AR, Osoba D, Hofstader SL, Goldstein MB, Cardella CJ, et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med. 1979;67:759–65.
Hassman LM, Ellison TJ, Kedes DH. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest. 2011;121:752–68.
Hayward GS, Zong JC. Modern evolutionary history of the human KSHV genome. Curr Top Microbiol Immunol. 2007;312:1–42.
Hjalgrim H, Melbye M, Pukkala E, Langmark F, Frisch M, et al. Epidemiology of Kaposi’s sarcoma in the Nordic countries before the AIDS epidemic. Br J Cancer. 1996;74:1499–502.
Hjalgrim H, Lind I, Rostgaard K, Melbye M, Frisch M, et al. Prevalence of human herpesvirus 8 antibodies in young adults in Denmark (1976–1977). J Natl Cancer Inst. 2001;93:1569–71.
Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. 2006;355:1331–8.
Hoischen SH, Vollmer P, Marz P, Ozbek S, Gotze KS, et al. Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. Eur J Biochem. 2000;267:3604–12.
Holst PJ, Rosenkilde MM, Manfra D, Chen SC, Wiekowski MT, et al. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J Clin Invest. 2001;108:1789–96.
Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet. 2004;36:683–5.
Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8. Blood. 1997;90:1186–91.
Hu J, Renne R. Characterization of the minimal replicator of Kaposi’s sarcoma-associated herpesvirus latent origin. J Virol. 2005;79:2637–42.
Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, et al. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet. 1981;2:598–600.
Iscovich J, Boffetta P, Winkelmann R, Brennan P, Azizi E. Classic Kaposi’s sarcoma in Jews living in Israel, 1961–1989: a population-based incidence study. AIDS. 1998;12:2067–72.
Iscovich J, Boffetta P, Winkelmann R, Brennan P, Azizi E. Classic Kaposi’s sarcoma in Jews living in Israel, 1961–1989: a population-based incidence study. AIDS. 1998;12:2067–72.
Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic kaposi sarcoma: epidemiology and risk factors. Cancer. 2000;88:500–17.
Iscovich J, Fischbein A, Fisher-Fischbein J, Freedman LS, Eng SM, et al. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus in healthy adults in Israel. Anticancer Res. 2000;20:2119–22.
Jalilvand S, Shoja Z, Mokhtari-Azad T, Nategh R, Gharehbaghian A. Seroprevalence of Human herpesvirus 8 (HHV-8) and incidence of Kaposi’s sarcoma in Iran. Infect Agent Cancer. 2011;6:5.
Jarviluoma A, Ojala PM. Cell signaling pathways engaged by KSHV. Biochim Biophys Acta. 2006;1766:140–58.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, et al. Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A. 2003;100:10399–404.
Juhasz A, Remenyik E, Konya J, Veress G, Begany A, et al. Prevalence and age distribution of human herpesvirus-8 specific antibodies in Hungarian blood donors. J Med Virol. 2001;64:526–30.
Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, et al. Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998;58:1599–604.
Kaasinen E, Aavikko M, Vahteristo P, Patama T, Li Y, Saarinen S, Kilpivaara O, Pitkänen E, Knekt P, Laaksonen M, Artama M, Lehtonen R, Aaltonen LA, Pukkala E. Nationwide registry-based analysis of cancer clustering detects strong familial occurrence of Kaposi sarcoma. PLoS One. 2013;8:e55209.
Kaldis P, Ojala PM, Tong L, Makela TP, Solomon MJ. CAK-independent activation of CDK6 by a viral cyclin. Mol Biol Cell. 2001;12:3987–99.
Kaleeba JA, Berger EA. Kaposi’s sarcoma-associated herpesvirus fusion-entry receptor: cystine transporter xCT. Science. 2006;311:1921–4.
Kaminer B, Murray JF. Sarcoma idiopathicum multiplex haemorrhagicum of Kaposi, with special reference to its incidence in the South African Negro, and two case reports. S Afr J Clin Sci. 1950;1:1–25.
Kasolo FC, Mpabalwani E, Gompels UA. Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi’s sarcoma in Africa. J Gen Virol. 1997;78:847–55.
Kazanji M, Dussart P, Duprez R, Tortevoye P, Pouliquen JF, et al. Serological and molecular evidence that human herpesvirus 8 is endemic among Amerindians in French Guiana. J Infect Dis. 2005;192:1525–9.
Kedes DH, Ganem D. Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest. 1997;99:2082–6.
Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996;2:918–24.
Kedes DH, Ganem D, Ameli N, Bacchetti P, Greenblatt R. The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV- seronegative women. JAMA. 1997;277:478–81.
Kimball LE, Casper C, Koelle DM, Morrow R, Corey L, Vieira J. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis. 2004;189:2016–22.
Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101:4115–21.
Kovaleva M, Bussmeyer I, Rabe B, Grotzinger J, Sudarman E, et al. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol. 2006;80:8510–20.
Krishnan HH, Naranatt PP, Smith MS, Zeng L, Bloomer C, Chandran B. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi’s sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol. 2004;78:3601–20.
Krown SE, Lee JY, Dittmer DP. More on HIV-associated Kaposi’s sarcoma. N Engl J Med. 2008;358:535–6.
Krown SE, Dittmer DP, Cesarman E. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. J Infect Dis. 2011;203:1082–6.
Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell. 2004;5:465–75.
Lagunoff M, Bechtel J, Venetsanakos E, Roy AM, Abbey N, et al. De novo infection and serial transmission of Kaposi’s sarcoma-associated herpesvirus in cultured endothelial cells. J Virol. 2002;76:2440–8.
Lampinen TM, Kulasingam S, Min J, Borok M, Gwanzura L, et al. Detection of Kaposi’s sarcoma-associated herpesvirus in oral and genital secretions of Zimbabwean women. J Infect Dis. 2000;181:1785–90.
Lan K, Kuppers DA, Verma SC, Robertson ES. Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. J Virol. 2004;78:6585–94.
Lan K, Kuppers DA, Verma SC, Sharma N, Murakami M, Robertson ES. Induction of Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J Virol. 2005;79:7453–65.
Landman R, Karsenty E, Katz L, Saimot AG. Kaposi’s sarcoma in Israel: epidemiologic data, 1960–1980. Bull Soc Pathol Exot Filiales. 1984;77:572–6.
Laney AS, Dollard SC, Jaffe HW, Offermann MK, Spira TJ, et al. Repeated measures study of human herpesvirus 8 (HHV-8) DNA and antibodies in men seropositive for both HHV-8 and HIV. AIDS. 2004;18:1819–26.
Laney AS, Peters JS, Manzi SM, Kingsley LA, Chang Y, Moore PS. Use of a multiantigen detection algorithm for diagnosis of Kaposi’s sarcoma-associated herpesvirus infection. J Clin Microbiol. 2006;44:3734–41.
Lavreys L, Chohan B, Ashley R, Richardson BA, Corey L, et al. Human herpesvirus 8: seroprevalence and correlates in prostitutes in Mombasa, Kenya. J Infect Dis. 2003;187:359–63.
Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS. 1998;12:F45–9.
Lee JS, Li Q, Lee JY, Lee SH, Jeong JH, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol. 2009;11:1355–62.
Lee HR, Brulois K, Wong L, Jung JU. Modulation of immune system by Kaposi’s sarcoma-associated herpesvirus: lessons from viral evasion strategies. Front Microbiol. 2012;3:44.
Lei X, Bai Z, Ye F, Xie J, Kim CG, et al. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat Cell Biol. 2010;12:193–9.
Lemma E, Constantine NT, Kassa D, Messele T, Mindaye T, et al. Human herpesvirus 8 infection in HIV-1-infected and uninfected pregnant women in Ethiopia. Ethiop Med J. 2009;47:205–11.
Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet. 1996;348:858–61.
Letang E, Almeida JM, Miro JM, Ayala E, White IE, et al. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in Mozambique: a prospective study. J Acquir Immune Defic Syndr. 2010;53:589–97.
Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi’s sarcoma. Eur J Cancer. 2001;37:1288–95.
Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, et al. Kaposi’s sarcoma-associated herpesvirus encodes a functional cyclin. J Virol. 1997;71:1984–91.
Liang D, Lin X, Lan K. Looking at Kaposi’s sarcoma-associated herpesvirus-host interactions from a microRNA viewpoint. Front Microbiol. 2011;2:271.
Lisco A, Barbierato M, Fiore JR, Gasperini P, Favia A, et al. Pregnancy and human herpesvirus 8 reactivation in human immunodeficiency virus type 1-infected women. J Clin Microbiol. 2006;44:3863–71.
Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science. 1993;259:946–51.
Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis. 2003;187:149–53.
Low W, Harries M, Ye H, Du MQ, Boshoff C, Collins M. Internal ribosome entry site regulates translation of Kaposi’s sarcoma-associated herpesvirus FLICE inhibitory protein. J Virol. 2001;75:2938–45.
Lubyova B, Pitha PM. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J Virol. 2000;74:8194–201.
Lubyova B, Kellum MJ, Frisancho AJ, Pitha PM. Kaposi’s sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7. J Biol Chem. 2004;279:7643–54.
Luppi M, Barozzi P, Santagostino G, Trovato R, Schulz TF, et al. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood. 2000;96:3279–81.
Luppi M, Barozzi P, Schulz TF, Setti G, Staskus K, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med. 2000;343:1378–85.
Malope BI, Pfeiffer RM, Mbisa G, Stein L, Ratshikhopha EM, et al. Transmission of Kaposi sarcoma-associated herpesvirus between mothers and children in a South African population. J Acquir Immune Defic Syndr. 2007;44:351–5.
Mancuso R, Biffi R, Valli M, Bellinvia M, Tourlaki A, et al. HHV8 a subtype is associated with rapidly evolving classic Kaposi’s sarcoma. J Med Virol. 2008;80:2153–60.
Mantina H, Kankasa C, Klaskala W, Brayfield B, Campbell J, et al. Vertical transmission of Kaposi’s sarcoma-associated herpesvirus. Int J Cancer. 2001;94:749–52.
Marcelin AG, Dupin N, Bossi P, Calvez V. Seroprevalence of human herpesvirus-8 in healthy subjects and patients with AIDS-associated and classical Kaposi’s sarcoma in France [letter]. AIDS. 1998;12:539–40.
Marcelin AG, Roque-Afonso AM, Hurtova M, Dupin N, Tulliez M, et al. Fatal disseminated Kaposi’s sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl. 2004;10:295–300.
Marcelin AG, Calvez V, Dussaix E. KSHV after an organ transplant: should we screen? Curr Top Microbiol Immunol. 2007;312:245–62.
Martin JN. Diagnosis and epidemiology of human herpesvirus 8 infection. Semin Hematol. 2003;40:133–42.
Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338:948–54.
Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, et al. Remission from Kaposi’s sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer. 2006;94:1000–6.
Martro E, Esteve A, Schulz TF, Sheldon J, Gambus G, et al. Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi’s sarcoma among men who have sex with men in a European multicentre study. Int J Cancer. 2007;120:1129–35.
Matondo P. Kaposi’s sarcoma in Africa. Clin Dermatol. 1999;17:197–207.
Matsumura S, Persson LM, Wong L, Wilson AC. The latency-associated nuclear antigen interacts with MeCP2 and nucleosomes through separate domains. J Virol. 2010;84:2318–30.
Matteoli B, Broccolo F, Scaccino A, Cottoni F, Angeloni A, et al. In vivo and in vitro evidence for an association between the route-specific transmission of HHV-8 and the virus genotype. J Med Virol. 2012;84:786–91.
Maurer T, Ponte M, Leslie K. HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007;357:1352–3.
Mayama S, Cuevas LE, Sheldon J, Omar OH, Smith DH, et al. Prevalence and transmission of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer. 1998;77:817–20.
Mbulaiteye SM, Biggar RJ, Bakaki PM, Pfeiffer RM, Whitby D, et al. Human herpesvirus 8 infection and transfusion history in children with sickle-cell disease in Uganda. J Natl Cancer Inst. 2003;95:1330–5.
Mbulaiteye SM, Pfeiffer RM, Whitby D, Brubaker GR, Shao J, Biggar RJ. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis. 2003;187:1780–5.
Mbulaiteye SM, Pfeiffer RM, Engels EA, Marshall V, Bakaki PM, et al. Detection of kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. J Infect Dis. 2004;190:1382–6.
Mbulaiteye SM, Biggar RJ, Pfeiffer RM, Bakaki PM, Gamache C, et al. Water, socioeconomic factors, and human herpesvirus 8 infection in Ugandan children and their mothers. J Acquir Immune Defic Syndr. 2005;38:474–9.
Mbulaiteye SM, Pfeiffer RM, Dolan B, Tsang VC, Noh J, et al. Seroprevalence and risk factors for human herpesvirus 8 infection, rural Egypt. Emerg Infect Dis. 2008;14:586–91.
McCarty KA, Bungu Z. Kaposi’s sarcoma in a two week old infant born to a mother with Kaposi’s sarcoma/AIDS. Cent Afr J Med. 1995;41:330–1.
McCormick C, Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science. 2005;307:739–41.
Meckes Jr DG, Gunawardena HP, Dekroon RM, Heaton PR, Edwards RH, Ozgur S, Griffith JD, Damania B, Raab-Traub N. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A. 2013;110:E2925–33.
Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi’s sarcoma-associated herpesvirus. AIDS. 1997;11:1327–32.
Mercader M, Taddeo B, Panella JR, Chandran B, Nickoloff BJ, Foreman KE. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol. 2000;156:1961–71.
Meschi S, Schepisi MS, Nicastri E, Bevilacqua N, Castilletti C, et al. The prevalence of antibodies to human herpesvirus 8 and hepatitis B virus in patients in two hospitals in Tanzania. J Med Virol. 2010;82:1569–75.
Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10:707–19.
Miller G, Rigsby MO, Heston L, Grogan E, Sun R, et al. Antibodies to butyrate-inducible antigens of Kaposi’s sarcoma- associated herpesvirus in patients with HIV-1 infection. N Engl J Med. 1996;334:1292–7.
Minhas V, Crabtree KL, Chao A, M’Soka TJ, Kankasa C, et al. Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. Am J Epidemiol. 2008;168:311–20.
Miyagi J, Masuda M, Uezato H, Sawada T, Miyakuni T, et al. Increased risk of human herpesvirus-8 infection in patients with adult T cell leukemia/lymphoma in Okinawa. Leukemia. 2002;16:1881–2.
Mohanna S, Ferrufino JC, Sanchez J, Bravo F, Gotuzzo E. Epidemiological and clinical characteristics of classic Kaposi’s sarcoma in Peru. J Am Acad Dermatol. 2005;53:435–41.
Mohanna S, Maco V, Bravo F, Gotuzzo E. Epidemiology and clinical characteristics of classic Kaposi’s sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease. Int J Infect Dis. 2005;9:239–50.
Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell. 2003;3:23–36.
Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and without HIV infection. N Engl J Med. 1995;332:1181–5.
Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996;274:1739–44.
Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, et al. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcomae. J Virol. 1996;70:549–58.
Moore PS, Kingsley LA, Holmberg SD, Spira T, Gupta P, et al. Kaposi’s sarcoma-associated herpesvirus infection prior to onset of Kaposi’s sarcoma. AIDS. 1996;10:175–80.
Moses AV, Fish KN, Ruhl R, Smith PP, Strussenberg JG, et al. Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol. 1999;73:6892–902.
Mseddi M, Abdelmaksoud W, Slah M, Taha JM, Bouassida S, et al. Kaposi’ s sarcoma. A series of 65 cases. Tunis Med. 2005;83:528–31.
Muller A, Bendick C, Salzberger B, Him S, Franzen C. Seroprevalence of human herpesvirus-8 in different patient groups in Cambodia and Germany. Eur J Clin Microbiol Infect Dis. 2001;20:291–3.
Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251–61.
Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Azumi N, et al. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) transforming gene. J Virol. 1998;72:4980–8.
Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi’s sarcoma. Cancer Cell. 2007;11:245–58.
Myoung J, Ganem D. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J Virol Methods. 2011;174:12–21.
Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe. 2009;5:376–85.
Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–56.
Nakamura S, Salahuddin SZ, Biberfeld P, Ensoli B, Markham PD, et al. Kaposi’s sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science. 1988;242:426–30.
Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. Global changes in Kaposi’s sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol. 2003;77:4205–20.
Nascimento MC, de Souza VA, Sumita LM, Freire W, Weiss HA, et al. Prevalence of, and risk factors for Kaposi’s sarcoma-associated herpesvirus infection among blood donors in Brazil: a multi-center serosurvey. J Med Virol. 2008;80:1202–10.
Nascimento MC, Sumita LM, Souza VU, Weiss HA, Oliveira J, et al. Seroprevalence of Kaposi sarcoma-associated herpesvirus and other serologic markers in the Brazilian Amazon. Emerg Infect Dis. 2009;15:663–7.
Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS. 2008;22:937–45.
Nuvor SV, Katano H, Ampofo WK, Barnor JS, Sata T. Higher prevalence of antibodies to human herpesvirus 8 in HIV-infected individuals than in the general population in Ghana, West Africa. Eur J Clin Microbiol Infect Dis. 2001;20:362–4.
Oettle AG. Geographical and racial differences in the frequency of Kaposi’s sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum. 1962;18:330–63. Monograph No.2.
Ojala PM, Yamamoto K, Castanos-Velez E, Biberfeld P, Korsmeyer SJ, Makela TP. The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol. 2000;2:819–25.
Okroj M, Spiller OB, Korodi Z, Tedeschi R, Dillner J, Blom AM. Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals. Vaccine. 2007;25:8102–9.
Olsen SJ, Chang Y, Moore PS, Biggar RJ, Melbye M. Increasing Kaposi’s sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi’s sarcoma endemic region, Zambia in 1985. AIDS. 1998;12:1921–5.
Olweny CLM, Friedman-Kien A, Laubenstein LJ. Epidemiology and clinical features of Kaposi’s sarcoma in tropical Africa. In: AIDS: the epidemic of Kaposi’s sarcoma and opportunistic infections. New York: Masson Publishing; 1984. p. 35–40.
Operskalski EA, Busch MP, Mosley JW, Kedes DH. Blood donations and viruses. Lancet. 1997;349:1327.
Orzechowska BU, Powers MF, Sprague J, Li H, Yen B, et al. Rhesus macaque rhadinovirus-associated non-Hodgkin lymphoma: animal model for KSHV-associated malignancies. Blood. 2008;112:4227–34.
Osmond DH, Buchbinder S, Cheng A, Graves A, Vittinghoff E, et al. Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA. 2002;287:221–5.
Ottinger M, Christalla T, Nathan K, Brinkmann MM, Viejo-Borbolla A, Schulz TF. Kaposi’s sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J Virol. 2006;80:10772–86.
Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in Indigenous Africans–burden, distribution, and trends. Lancet Oncol. 2008;9:683–92.
Parravicini C, Olsen SJ, Capra M, Poli F, Sirchia G, et al. Risk of Kaposi’s sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi’s sarcoma patients. Blood. 1997;90:2826–9.
Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol. 2000;156:743–9.
Parsons CH, Adang LA, Overdevest J, O’Connor CM, Taylor Jr JR, et al. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J Clin Invest. 2006;116:1963–73.
Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med. 2000;343:1369–77.
Pellett PE, Wright DJ, Engels EA, Ablashi DV, Dollard SC, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion. 2003;43:1260–8.
Penn I. Cancers following cyclosporine therapy. Transplantation. 1987;43:32–5.
Penn I. Neoplastic consequences of transplantation and chemotherapy. Cancer Detect Prev Suppl. 1987;1:149–57.
Penn I. Sarcomas in organ allograft recipients. Transplantation. 1995;60:1485–91.
Perez CL, Tous MI, Zala N, Camino S. Human herpesvirus 8 in healthy blood donors, Argentina. Emerg Infect Dis. 2010;16:150–1.
Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, et al. Identification of microRNAs of the herpesvirus family. Nat Methods. 2005;2:269–76.
Pfeiffer RM, Wheeler WA, Mbisa G, Whitby D, Goedert JJ, et al. Geographic heterogeneity of prevalence of the human herpesvirus 8 in sub-Saharan Africa: clues about etiology. Ann Epidemiol. 2010;20:958–63.
Picchio GR, Sabbe RE, Gulizia RJ, McGrath M, Herndier BG, Mosier DE. The KSHV/HHV8-infected BCBL-1 lymphoma line causes tumors in SCID mice but fails to transmit virus to a human peripheral blood mononuclear cell graft. Virology. 1997;238:22–9.
Plancoulaine S, Abel L, van Beveren M, Tregouet DA, Joubert M, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet. 2000;356:1062–5.
Plancoulaine S, Abel L, Tregouet D, Duprez R, van Beveren M, et al. Respective roles of serological status and blood specific antihuman herpesvirus 8 antibody levels in human herpesvirus 8 intrafamilial transmission in a highly endemic area. Cancer Res. 2004;64:8782–7.
Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012;3:73.
Prasad A, Remick J, Zeichner SL. Activation of human herpesvirus replication by apoptosis. J Virol. 2013;87:10641–50.
Punj V, Matta H, Schamus S, Tamewitz A, Anyang B, Chaudhary PM. Kaposi’s sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a. Oncogene. 2010;29:1835–44.
Qunibi W, Akhtar M, Sheth K, Ginn HE, Al-Furayh O, et al. Kaposi’s sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med. 1988;84:225–32.
Raab MS, Albrecht JC, Birkmann A, Yağuboğlu S, et al. The immunogenic glycoprotein gp35-37 of human herpesvirus 8 is encoded by open reading frame K8.1. J Virol. 1998;72:6725–31.
Rabkin CS, Schulz TF, Whitby D, Lennette ET, Magpantay LI, et al. Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis. 1998;178:304–9.
Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med. 2000;6:1121–7.
Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, et al. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol. 1997;71:5915–21.
Rappocciolo G, Jenkins FJ, Hensler HR, Piazza P, Jais M, et al. DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J Immunol. 2006;176:1741–9.
Regamey N, Cathomas G, Schwager M, Wernli M, Harr T, Erb P. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol. 1998;36:1784–6.
Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients [see comments]. N Engl J Med. 1998;339:1358–63.
Renne R, Zhong W, Herndier B, McGrath M, Abbey N, et al. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996;2:342–6.
Renne R, Dittmer D, Kedes D, Schmidt K, Desrosiers RC, et al. Experimental transmission of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) to SIV-positive and SIV-negative rhesus macaques. J Med Primatol. 2004;33:1–9.
Renwick N, Dukers NH, Weverling GJ, Sheldon JA, Schulz TF, et al. Risk factors for human herpesvirus 8 infection in a cohort of drug users in the Netherlands, 1985–1996. J Infect Dis. 2002;185:1808–12.
Rezza G, Andreoni M, Dorrucci M, Pezzotti P, Monini P, et al. Human herpesvirus 8 seropositivity and risk of Kaposi’s sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst. 1999;91:1468–74.
Rezza G, Tchangmena OB, Andreoni M, Bugarini R, Toma L, et al. Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon. Sex Transm Dis. 2000;27:159–64.
Rezza G, Danaya RT, Wagner TM, Sarmati L, Owen IL, et al. Human herpesvirus-8 and other viral infections, Papua New Guinea. Emerg Infect Dis. 2001;7:893–5.
Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi’s sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol. 2001;75:429–38.
Rose TM, Strand KB, Schultz ER, Schaefer G, Rankin Jr GW, et al. Identification of two homologs of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species. J Virol. 1997;71:4138–44.
Rosen N, Watters AK, Brassard A. Classic Kaposi’s sarcoma in the Inuit of northern Quebec. J Am Acad Dermatol. 2005;52:31–4.
Ross RK, Casagrande JT, Dworsky RL, Levine A, Mack T. Kaposi’s sarcoma in Los Angeles, California. J Natl Cancer Inst. 1985;75:1011–5.
Roth WK, Brandstetter H, Sturzl M. Cellular and molecular features of HIV-associated Kaposi’s sarcoma [editorial]. AIDS. 1992;6:895–913.
Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A. 1996;93:14862–7.
Sadler R, Wu L, Forghani B, Renne R, Zhong W, et al. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi’s sarcoma-associated herpesvirus. J Virol. 1999;73:5722–30.
Samols MA, Skalsky RL, Maldonado AM, Riva A, Lopez MC, et al. Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog. 2007;3:e65.
Santarelli R, De Marco R, Masala MV, Angeloni A, Uccini S, et al. Direct correlation between human herpesvirus-8 seroprevalence and classic Kaposi’s sarcoma incidence in Northern Sardinia. J Med Virol. 2001;65:368–72.
Sarek G, Kurki S, Enback J, Iotzova G, Haas J, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest. 2007;117:1019–28.
Sarid R, Gao SJ. Viruses and human cancer: from detection to causality. Cancer Lett. 2011;305:218–27.
Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol. 1998;72:1005–12.
Sarid R, Olsen SJ, Moore PS. Kaposi’s sarcoma-associated herpesvirus epidemiology, virology, and molecular biology. Adv Virus Res. 1999;52:139–232.
Sarid R, Wiezorek JS, Moore PS, Chang Y. Characterization and cell cycle regulation of the major Kaposi’s sarcoma-associated herpesvirus (Human herpesvirus 8) latent genes and their promoter. J Virol. 1999;73:1438–46.
Sarid R, Pizov G, Rubinger D, Backenroth R, Friedlaender MM, et al. Detection of human herpesvirus-8 DNA in kidney allografts prior to the development of Kaposi’s sarcoma. Clin Infect Dis. 2001;32:1502–5.
Sarmati L. HHV-8 infection in African children. Herpes. 2004;11:50–3.
Sathish N, Wang X, Yuan Y. Tegument proteins of Kaposi’s sarcoma-associated herpesvirus and related gamma-herpesviruses. Front Microbiol. 2012;3:98.
Searles RP, Bergquam EP, Axthelm MK, Wong SW. Sequence and genomic analysis of a rhesus macaque rhadinovirus with similarity to Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8. J Virol. 1999;73:3040–53.
Sergerie Y, Abed Y, Roy J, Boivin G. Comparative evaluation of three serological methods for detection of human herpesvirus 8-specific antibodies in Canadian allogeneic stem cell transplant recipients. J Clin Microbiol. 2004;42:2663–7.
Serraino D, Franceschi S, Dal Maso L, La Vecchia C. HIV transmission and Kaposi’s sarcoma among European women. AIDS. 1995;9:971–3.
Serraino D, Toma L, Andreoni M, Butto S, Tchangmena O, et al. A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. Eur J Epidemiol. 2001;17:871–6.
Shebl FM, Dollard SC, Pfeiffer RM, Biryahwaho B, Amin MM, et al. Human herpesvirus 8 seropositivity among sexually active adults in Uganda. PLoS One. 2011;6:e21286.
Si H, Robertson ES. Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol. 2006;80:697–709.
Siegel JH, Janis R, Alper JC, Schutte H, Robbins L, Blaufox MD. Disseminated visceral Kaposi’s sarcoma. Appearance after human renal homograft operation. JAMA. 1969;207:1493–6.
Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, et al. Prevalence of Kaposi’s sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996;348:1133–8.
Sirianni MC, Vincenzi L, Topino S, Giovannetti A, Mazzetta F, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi’s sarcoma. Eur J Immunol. 2002;32:2711–20.
Sitas F, Newton R. Kaposi’s sarcoma in South Africa. J Natl Cancer Inst Monogr. 2001;1–4.
Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, et al. Kaposi’s sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol. 2007;81:12836–45.
Smith NA, Sabin CA, Gopal R, Bourboulia D, Labbet W, et al. Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis. 1999;180:600–6.
Song J, Ohkura T, Sugimoto M, Mori Y, Inagi R, et al. Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line. J Med Virol. 2002;68:404–11.
Sosa C, Klaskala W, Chandran B, Soto R, Sieczkowski L, et al. Human herpesvirus 8 as a potential sexually transmitted agent in Honduras. J Infect Dis. 1998;178:547–51.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80.
Spina M, Gaidano G, Carbone A, Capello D, Tirelli U. Highly active antiretroviral therapy in human herpesvirus-8-related body-cavity-based lymphoma. AIDS. 1998;12:955–6.
Spira TJ, Lam L, Dollard SC, Meng YX, Pau CP, et al. Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J Clin Microbiol. 2000;38:2174–80.
Srinivasan V, Komatsu T, Ballestas ME, Kaye KM. Definition of sequence requirements for latency-associated nuclear antigen 1 binding to Kaposi’s sarcoma-associated herpesvirus DNA. J Virol. 2004;78:14033–8.
Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, et al. Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol. 1997;71:715–9.
Stebbing J, Gazzard B, Newsom-Davis T, Nelson M, Patterson S, et al. Nadir B cell counts are significantly correlated with the risk of Kaposi’s sarcoma. Int J Cancer. 2004;108:473–4.
Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi’s sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006;367:1495–502.
Stratigos AJ, Malanos D, Touloumi G, Antoniou A, Potouridou I, et al. Association of clinical progression in classic Kaposi’s sarcoma with reduction of peripheral B lymphocytes and partial increase in serum immune activation markers. Arch Dermatol. 2005;141:1421–6.
Stürzl M, Gaus D, Dirks WG, Ganem D, Jochmann R. Kaposi’s sarcoma-derived cell line SLK is not of endothelial origin, but is a contaminant from a known renal carcinoma cell line. Int J Cancer. 2013;132:1954–8.
Suchankova A, Stankova M, Roubalova K, Vandasova J, Bruckova M. Seroprevalence of HHV 8 antibodies among the general population and HIV positive persons in the Czech Republic. J Clin Virol. 2003;28:70–6.
Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, et al. Kinetics of Kaposi’s sarcoma-associated herpesvirus gene expression. J Virol. 1999;73:2232–42.
Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature. 1997;390:184–7.
Szekely L, Chen F, Teramoto N, Ehlin-Henriksson B, Pokrovskaja K, et al. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line. J Gen Virol. 1998;79:1445–52.
Tanzi E, Zappa A, Caramaschi F, Amendola A, Lasagna D, et al. Human herpesvirus type 8 infection in an area of Northern Italy with high incidence of classical Kaposi’s sarcoma. J Med Virol. 2005;76:571–5.
Taylor MM, Chohan B, Lavreys L, Hassan W, Huang ML, et al. Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis. 2004;190:484–8.
Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi’s sarcoma. J Clin Microbiol. 2001;39:4269–73.
Tedeschi R, Bidoli E, Agren A, Hallmans G, Wadell G, et al. Epidemiology of Kaposi’s Sarcoma herpesvirus (HHV8) in Vasterbotten County, Sweden. J Med Virol. 2006;78:372–8.
Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997;386:517–21.
Tomkowicz B, Singh SP, Lai D, Singh A, Mahalingham S, et al. Mutational analysis reveals an essential role for the LXXLL motif in the transformation function of the human herpesvirus-8 oncoprotein, kaposin. DNA Cell Biol. 2005;24:10–20.
Toschi E, Sgadari C, Monini P, Barillari G, Bacigalupo I, et al. Treatment of Kaposi’s sarcoma–an update. Anticancer Drugs. 2002;13:977–87.
Trus BL, Heymann JB, Nealon K, Cheng N, Newcomb WW, et al. Capsid structure of Kaposi’s sarcoma-associated herpesvirus, a gammaherpesvirus, compared to those of an alphaherpesvirus, herpes simplex virus type 1, and a betaherpesvirus, cytomegalovirus. J Virol. 2001;75:2879–90.
Uldrick TS, Wang V, O’Mahony D, Aleman K, Wyvill KM, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51:350–8.
Varthakavi V, Browning PJ, Spearman P. Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi’s sarcoma-associated herpesvirus. J Virol. 1999;73:10329–38.
Verma SC, Lan K, Robertson E. Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol. 2007;312:101–36.
Verschuren EW, Klefstrom J, Evan GI, Jones N. The oncogenic potential of Kaposi’s sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell. 2002;2:229–41.
Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 2004;64:581–9.
Vieira J, O’Hearn PM. Use of the red fluorescent protein as a marker of Kaposi’s sarcoma-associated herpesvirus lytic gene expression. Virology. 2004;325:225–40.
Vieira J, Huang ML, Koelle DM, Corey L. Transmissible Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi’s sarcoma. J Virol. 1997;71:7083–7.
Vieira J, O’Hearn P, Kimball L, Chandran B, Corey L. Activation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol. 2001;75:1378–86.
Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989–91: changes in incidence in the era of AIDS. Int J Cancer. 1993;54:26–36.
Walter PR, Philippe E, Nguemby-Mbina C, Chamlian A. Kaposi’s sarcoma: presence of herpes-type virus particles in a tumor specimen. Hum Pathol. 1984;15:1145–6.
Wang L, Damania B. Kaposi’s sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res. 2008;68:4640–8.
Wang QJ, Jenkins FJ, Jacobson LP, Kingsley LA, Day RD, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood. 2001;97:2366–73.
Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004;36:687–93.
Watanabe T, Sugaya M, Atkins AM, Aquilino EA, Yang A, et al. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol. 2003;77:6188–96.
West JT, Wood C. The role of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene. 2003;22:5150–63.
Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet. 1995;346:799–802.
Whitby D, Luppi M, Barozzi P, Boshoff C, Weiss RA, Torelli G. Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst. 1998;90:395–7.
Whitby D, Smith NA, Matthews S, O’Shea S, Sabin CA, et al. Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. J Infect Dis. 1999;179:234–6.
Whitby D, Marshall VA, Bagni RK, Miley WJ, McCloud TG, et al. Reactivation of Kaposi’s sarcoma-associated herpesvirus by natural products from Kaposi’s sarcoma endemic regions. Int J Cancer. 2007;120:321–8.
Wies E, Mori Y, Hahn A, Kremmer E, Sturzl M, et al. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood. 2008;111:320–7.
Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, et al. Identification of Kaposi’s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol. 2002;76:2634–40.
Wit FW, Sol CJ, Renwick N, Roos MT, Pals ST, et al. Regression of AIDS-related Kaposi’s sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS. 1998;12:218–9.
Wong SW, Bergquam EP, Swanson RM, Lee FW, Shiigi SM, et al. Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi’s sarcoma-associated herpesvirus. J Exp Med. 1999;190:827–40.
Ye FC, Zhou FC, Yoo SM, Xie JP, Browning PJ, Gao SJ. Disruption of Kaposi’s sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol. 2004;78:11121–9.
Ye F, Zhou F, Bedolla RG, Jones T, Lei X, et al. Reactive oxygen species hydrogen peroxide mediates Kaposi’s sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 2011;7:e1002054.
Yoo J, Kang J, Lee HN, Aguilar B, Kafka D, et al. Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi’s sarcoma herpes virus. PLoS Pathog. 2010;6:e1001046.
Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity. 2005;22:59–70.
Zavitsanou A, Sypsa V, Petrodaskalaki M, Kalapothaki V, Whitby D, Hatzakis A. Human herpesvirus 8 (HHV-8) infection in healthy urban employees from Greece: seroprevalence and associated factors. J Med Virol. 2007;79:591–6.
Zhang H, Yang XY, Hong T, Feldman T, Bhattacharyya PK. Kaposi sarcoma-associated herpesvirus (human herpesvirus type 8)-associated extracavitary lymphoma: report of a case in an HIV-positive patient with simultaneous Kaposi sarcoma and a review of the literature. Acta Haematol. 2010;123:237–41.
Zhang T, Shao X, Chen Y, Minhas V, Wood C, He N. Human herpesvirus 8 seroprevalence, China. Emerg Infect Dis. 2012;18:150–2.
Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A. 1996;93:6641–6.
Zhou FC, Zhang YJ, Deng JH, Wang XP, Pan HY, et al. Efficient infection by a recombinant Kaposi’s sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol. 2002;76:6185–96.
Zhu L, Wang R, Sweat A, Goldstein E, Horvat R, Chandran B. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Virology. 1999;256:381–92.
Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y. A Kaposi’s sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci U S A. 2002;99:5573–8.
Zhu FX, Chong JM, Wu L, Yuan Y. Virion proteins of Kaposi’s sarcoma-associated herpesvirus. J Virol. 2005;79:800–11.
Ziegler JL, Katongole-Mbidde E. Kaposi’s sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer. 1996;65:200–3.
Ziegler JL, Newton R, Katongole-Mbidde E, Mbulataiye S, De Cock K, et al. Risk factors for Kaposi’s sarcoma in HIV-positive subjects in Uganda. AIDS. 1997;11:1619–26.
Ziegler JL, Simonart T, Snoeck R. Kaposi’s sarcoma, oncogenic viruses, and iron. J Clin Virol. 2001;20:127–30.
Zoeteweij JP, Moses AV, Rinderknecht AS, Davis DA, Overwijk WW, et al. Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. Blood. 2001;97:2374–80.
Zong J, Ciufo DM, Viscidi R, Alagiozoglou L, Tyring S, et al. Genotypic analysis at multiple loci across Kaposi’s sarcoma herpesvirus (KSHV) DNA molecules: clustering patterns, novel variants and chimerism. J Clin Virol. 2002;23:119–48.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sarid, R., Calabrò, M.L. (2014). Kaposi’s Sarcoma-Associated Herpesvirus: Epidemiology, Biological Characteristics and Pathogenesis. In: Kaslow, R., Stanberry, L., Le Duc, J. (eds) Viral Infections of Humans. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7448-8_39
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7448-8_39
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7447-1
Online ISBN: 978-1-4899-7448-8
eBook Packages: MedicineMedicine (R0)